^
BIOMARKER:

MET amplification

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/14/2022
Initiation :
05/22/2020
Primary completion :
05/01/2022
Completion :
05/01/2022
PD-L1 • ALK • RET • ROS1
|
EGFR L858R • MET amplification • EGFR exon 19 deletion • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • RET rearrangement • EGFR G719X • EGFR negative • MET-H
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Abraxane (albumin-bound paclitaxel) • Cyramza (ramucirumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
Phase 1/2
Criterium, Inc.
Not yet recruiting
Last update posted :
01/13/2022
Initiation :
03/01/2022
Primary completion :
06/30/2025
Completion :
07/31/2027
EGFR • ALK • MET
|
MET amplification • MET exon 14 mutation • MET fusion
|
Tepmetko (tepotinib)
Phase 2
AstraZeneca
Recruiting
Last update posted :
01/12/2022
Initiation :
01/09/2019
Primary completion :
09/30/2022
Completion :
09/30/2022
EGFR • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion • EGFR amplification • MET overexpression
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/11/2022
Initiation :
01/30/2019
Primary completion :
01/31/2022
Completion :
01/31/2022
BRAF • KRAS • MET • MSI
|
MET amplification • KRAS wild-type • NRAS wild-type
|
Orpathys (savolitinib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/06/2022
Initiation :
03/01/2018
Primary completion :
12/31/2022
Completion :
12/31/2022
EGFR • PD-L1 • ALK • RET • ROS1
|
EGFR L858R • MET amplification • EGFR exon 19 deletion • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • RET rearrangement • EGFR G719X • EGFR negative • MET-H
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1/2
Shanghai EpimAb Biotherapeutics Co., Ltd.
Recruiting
Last update posted :
01/04/2022
Initiation :
10/21/2021
Primary completion :
08/04/2024
Completion :
08/31/2024
EGFR • MET
|
EGFR mutation • MET amplification • EGFR expression • EGFR overexpression • MET overexpression
|
EMB-01
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
12/31/2021
Initiation :
05/24/2016
Primary completion :
01/04/2024
Completion :
01/04/2024
ALK • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • MET expression • EGFR wild-type
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 1/2
Amgen
Completed
Last update posted :
12/28/2021
Initiation :
04/15/2014
Primary completion :
11/05/2015
Completion :
12/07/2018
MET
|
MET amplification
|
AMG 337
Phase 2
AstraZeneca
Recruiting
Last update posted :
12/20/2021
Initiation :
09/28/2020
Primary completion :
02/27/2023
Completion :
02/29/2024
EGFR • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
Phase 2
Guangdong Association of Clinical Trials
Not yet recruiting
Last update posted :
12/20/2021
Initiation :
12/01/2021
Primary completion :
12/01/2023
Completion :
08/01/2026
MET
|
EGFR mutation • MET amplification • MET overexpression • MET expression • MET-H
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
12/16/2021
Initiation :
12/02/2021
Primary completion :
11/01/2023
Completion :
11/01/2023
HER-2
|
MET amplification • EGFR amplification
|
Rybrevant (amivantamab-vmjw)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/14/2021
Initiation :
10/15/2018
Primary completion :
12/31/2023
Completion :
12/31/2023
MET
|
MET amplification • MET mutation • MET fusion • HGF amplification
|
Orpathys (savolitinib)
Phase 2
University Health Network, Toronto
Recruiting
Last update posted :
12/09/2021
Initiation :
12/03/2019
Primary completion :
12/01/2024
Completion :
06/01/2025
MET • ROS1
|
MET amplification • MET exon 14 mutation • ROS1 rearrangement • MET mutation
|
Xalkori (crizotinib)
Phase 2
EMD Serono Research & Development Institute, Inc.
Recruiting
Last update posted :
12/08/2021
Initiation :
09/19/2019
Primary completion :
11/30/2022
Completion :
03/30/2023
EGFR • MET
|
EGFR mutation • MET amplification
|
Tagrisso (osimertinib) • Tepmetko (tepotinib)
Phase 3
Novartis Pharmaceuticals
Recruiting
Last update posted :
12/06/2021
Initiation :
09/22/2021
Primary completion :
10/28/2025
Completion :
03/30/2027
EGFR • MET
|
EGFR mutation • MET amplification • EGFR T790M negative
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Tabrecta (capmatinib)
Phase 3
Hutchison Medipharma Limited
Recruiting
Last update posted :
11/30/2021
Initiation :
11/22/2021
Primary completion :
09/15/2024
Completion :
11/30/2024
MET
|
EGFR mutation • MET amplification
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)
Phase 2
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Last update posted :
11/25/2021
Initiation :
11/01/2021
Primary completion :
12/01/2023
Completion :
06/01/2025
HER-2 • MET
|
HER-2 positive • MET amplification
|
spartalizumab (PDR001) • Tabrecta (capmatinib)
Phase 1/2
RemeGen Co., Ltd.
Active, not recruiting
Last update posted :
11/25/2021
Initiation :
09/26/2018
Primary completion :
08/19/2021
Completion :
05/30/2022
HER-2 • MET
|
EGFR mutation • HER-2 overexpression • EGFR T790M • MET amplification • HER-2 mutation • MET mutation • HER-2 exon 20 mutation
|
Aidixi (disitamab vedotin)
Phase 2
EMD Serono Research & Development Institute, Inc.
Active, not recruiting
Last update posted :
11/24/2021
Initiation :
01/28/2021
Primary completion :
03/23/2023
Completion :
03/23/2023
BRAF • MET
|
MET amplification • BRAF wild-type
|
Erbitux (cetuximab) • Tepmetko (tepotinib)
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
11/23/2021
Initiation :
12/30/2021
Primary completion :
09/21/2023
Completion :
09/04/2028
MET
|
MET amplification • MET exon 14 mutation • MET mutation
|
Tabrecta (capmatinib)
Phase 1b
M.D. Anderson Cancer Center
Recruiting
Last update posted :
11/19/2021
Initiation :
12/01/2020
Primary completion :
09/03/2025
Completion :
09/03/2025
ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D
|
MET amplification • MET mutation • ALK translocation • MET expression • MET-H
|
Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • Inlyta (axitinib)
Phase 1/2
Regeneron Pharmaceuticals
Recruiting
Last update posted :
10/29/2021
Initiation :
01/07/2020
Primary completion :
10/20/2024
Completion :
10/20/2024
MET
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression
|
REGN5093
Phase N/A
Centre Leon Berard
Recruiting
Last update posted :
10/08/2021
Initiation :
07/01/2015
Primary completion :
03/01/2026
Completion :
12/01/2026
HER-2 • BRAF • PD-L1 • ALK • MET • ROS1
|
EGFR mutation • BRAF mutation • MET amplification • HER-2 mutation • RET rearrangement • ALK translocation
Phase 1/2
Merck KGaA, Darmstadt, Germany
Completed
Last update posted :
09/28/2021
Initiation :
12/23/2013
Primary completion :
12/12/2017
Completion :
08/12/2021
MET
|
EGFR mutation • MET amplification • MET overexpression • EGFR T790M negative
|
cisplatin • gefitinib • carboplatin • pemetrexed • Tepmetko (tepotinib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
05/08/2017
Primary completion :
06/30/2021
Completion :
07/01/2022
MET • RET • AXL
|
MET amplification • MET overexpression • RET mutation • RET rearrangement • MET mutation • AXL overexpression
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 2
Hutchison Medipharma Limited
Recruiting
Last update posted :
09/02/2021
Initiation :
07/27/2021
Primary completion :
12/01/2024
Completion :
03/01/2025
MET
|
MET amplification
|
Orpathys (savolitinib)
Phase N/A
Chonnam National University Hospital
Completed
Last update posted :
08/03/2021
Initiation :
09/01/2011
Primary completion :
09/01/2014
Completion :
11/01/2017
EGFR • MET
|
EGFR mutation • MET amplification • EGFR expression • MET mutation • MET expression
|
erlotinib
Phase 1
University of Oxford
Completed
Last update posted :
07/13/2021
Initiation :
11/01/2014
Primary completion :
12/03/2018
Completion :
12/03/2018
KRAS • NRAS • MET
|
MET amplification • MET overexpression • MET mutation • MET expression
|
Xalkori (crizotinib) • Mektovi (binimetinib) • mirdametinib (PD-0325901)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
06/09/2021
Initiation :
02/17/2015
Primary completion :
12/31/2022
Completion :
12/31/2023
MET • IL6 • CHGA • CRP
|
MET amplification • MET expression
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 1/2
LaNova Medicines Limited
Recruiting
Last update posted :
05/31/2021
Initiation :
05/20/2021
Primary completion :
07/30/2023
Completion :
08/30/2024
EGFR • MET
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression
|
LM-061
Phase N/A
AstraZeneca
Completed
Last update posted :
05/27/2021
Initiation :
05/26/2016
Primary completion :
05/31/2020
Completion :
05/31/2020
EGFR • HER-2 • MET
|
EGFR mutation • HER-2 amplification • EGFR L858R • EGFR T790M • MET amplification • MET mutation
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
05/20/2021
Initiation :
11/01/2014
Primary completion :
01/04/2019
Completion :
03/17/2020
HER-2
|
HER-2 positive • MET amplification
|
Herceptin (trastuzumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase N/A
University Health Network, Toronto
Active, not recruiting
Last update posted :
04/27/2021
Initiation :
03/01/2018
Primary completion :
02/01/2023
Completion :
02/01/2023
EGFR • MET
|
MET amplification • MET exon 14 mutation
Phase 1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recruiting
Last update posted :
04/01/2021
Initiation :
02/23/2021
Primary completion :
03/01/2022
Completion :
03/01/2022
ALK • MET • ROS1
|
MET amplification • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • ALK-ROS1 fusion
|
TQ-B3139
Phase N/A
Lung Cancer Mutation Consortium
Not yet recruiting
Last update posted :
03/04/2021
Initiation :
04/01/2021
Primary completion :
07/01/2023
Completion :
11/01/2023
EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK
|
BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • RET rearrangement • ROS1 rearrangement • MET mutation • MET amplification + MET Exon 14 mutation
Phase 1
Instituto Oncológico Dr Rosell
Not yet recruiting
Last update posted :
02/26/2021
Initiation :
04/01/2021
Primary completion :
04/01/2026
Completion :
06/01/2026
EGFR • ALK • MET • ROS1 • HAVCR2 • NTRK
|
EGFR mutation • EGFR T790M • MET amplification • EGFR C797S • EGFR exon 18 mutation
|
Tagrisso (osimertinib) • repotrectinib (TPX-0005)
Phase 1
John Strickler, M.D.
Completed
Last update posted :
02/12/2021
Initiation :
01/01/2014
Primary completion :
05/10/2018
Completion :
08/29/2018
KRAS • MET
|
MET amplification • RAS wild-type • KRAS wild-type
|
Vectibix (panitumumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase N/A
The Netherlands Cancer Institute
Recruiting
Last update posted :
01/27/2021
Initiation :
07/17/2019
Primary completion :
10/01/2021
Completion :
10/01/2021
EGFR • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion
|
Xalkori (crizotinib) • Tagrisso (osimertinib)
Phase 1a
Symphogen A/S
Completed
Last update posted :
01/13/2021
Initiation :
03/01/2016
Primary completion :
12/01/2020
Completion :
12/01/2020
EGFR • KRAS • MET
|
MET amplification • RAS wild-type • KRAS wild-type
|
Sym015
Phase 1
Turning Point Therapeutics, Inc.
Recruiting
Last update posted :
12/29/2020
Initiation :
08/20/2019
Primary completion :
11/01/2022
Completion :
11/01/2023
MET
|
MET amplification • MET exon 14 mutation • MET exon 14 deletion
|
elzovantinib (TPX-0022)
Phase N/A
AstraZeneca
Completed
Last update posted :
12/23/2020
Initiation :
05/07/2019
Primary completion :
12/31/2019
Completion :
12/31/2019
EGFR • HER-2 • ALK • TP53 • MET
|
PD-L1 expression • EGFR mutation • HER-2 amplification • EGFR T790M • MET amplification • EGFR exon 19 deletion • MET expression
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
09/29/2020
Initiation :
06/01/2012
Primary completion :
01/01/2017
Completion :
06/01/2019
MET
|
MET amplification
|
Cabometyx (cabozantinib tablet)
Phase 2
National University Hospital, Singapore
Not yet recruiting
Last update posted :
08/31/2020
Initiation :
09/01/2020
Primary completion :
09/01/2023
Completion :
09/01/2023
TP53 • MET
|
TP53 mutation • HER-2 amplification • MET amplification • MET mutation • MET N375S • HER-2 amplification + MET amplification
|
Gilotrif (afatinib)
Phase 2
Cancer Institute and Hospital, Chinese Academy ...
Not yet recruiting
Last update posted :
08/04/2020
Initiation :
08/15/2020
Primary completion :
07/01/2022
Completion :
07/01/2023
EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
|
BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 amplification • HER-2 overexpression • BRAF mutation • MET amplification • KIT mutation • ALK fusion • CDKN2A mutation • ROS1 fusion • MET mutation • BRAF amplification
|
Xalkori (crizotinib) • Zelboraf (vemurafenib) • Ibrance (palbociclib) • imatinib • Tecentriq (atezolizumab) • Alecensa (alectinib) • Zejula (niraparib) • Tyvyt (sintilimab) • Irene (pyrotinib) • Vizimpro (dacomitinib) • Ameile (aumolertinib)
Phase 1
EMD Serono
Completed
Last update posted :
08/04/2020
Initiation :
11/30/2009
Primary completion :
10/31/2015
Completion :
10/31/2015
MET
|
MET amplification • MET mutation
|
Tepmetko (tepotinib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/14/2020
Initiation :
04/29/2013
Primary completion :
09/12/2019
MET
|
MET amplification
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 1/2
Children's Oncology Group
Completed
Last update posted :
06/09/2020
Initiation :
09/21/2009
Primary completion :
12/31/2018
Completion :
12/31/2018
ALK • MET • HGF
|
MET amplification • ALK fusion • ALK mutation • MET mutation • ALK amplification
|
Xalkori (crizotinib)
Phase 1
Henlix, Inc
Recruiting
Last update posted :
05/01/2020
Initiation :
03/03/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
KRAS • MET
|
MET amplification • MET overexpression • MET exon 14 mutation • MET mutation
|
HLX55
Phase 1
ShangHai HaiHe Pharmaceutical
Recruiting
Last update posted :
03/11/2020
Initiation :
09/14/2017
Primary completion :
10/01/2021
Completion :
10/01/2021
EGFR • KRAS • ALK • MET • ROS1
|
EGFR mutation • MET amplification • MET overexpression • MET exon 14 mutation • ALK mutation • MET mutation
|
glumetinib (SCC244)
Phase 2
Mirati Therapeutics Inc.
Completed
Last update posted :
03/04/2020
Initiation :
10/01/2015
Primary completion :
04/30/2018
Completion :
01/01/2019
MET
|
MET amplification • MET mutation
|
glesatinib (MGCD265)
Phase 2
Samsung Medical Center
Recruiting
Last update posted :
01/22/2020
Initiation :
02/10/2016
Primary completion :
12/01/2020
Completion :
12/01/2020
MET
|
MET amplification
|
Orpathys (savolitinib)
Phase 1
Fujian Cosunter Pharmaceutical Co. Ltd
Recruiting
Last update posted :
01/14/2020
Initiation :
07/01/2019
Primary completion :
09/30/2020
Completion :
12/31/2020
MET
|
MET amplification • MET positive • MET expression
|
GST-HG16
Phase 2
Samsung Medical Center
Recruiting
Last update posted :
12/30/2019
Initiation :
04/30/2015
Primary completion :
12/01/2020
Completion :
12/01/2020
MET
|
MET amplification
|
docetaxel • Orpathys (savolitinib)
Phase 1
M.D. Anderson Cancer Center
Completed
Last update posted :
07/16/2019
Initiation :
03/01/2013
Primary completion :
03/01/2019
Completion :
03/01/2019
BRAF • ALK • MET • CDKN2A • DDR2 • CTGF
|
BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification
|
Xalkori (crizotinib) • dasatinib
Phase 
National University Hospital, Singapore
Recruiting
Last update posted :
05/06/2019
Initiation :
10/03/2017
Primary completion :
10/01/2021
Completion :
10/01/2022
TP53 • MET
|
TP53 mutation • HER-2 amplification • MET amplification • MET mutation • MET N375S • HER-2 amplification + MET amplification
Phase 2
Fondazione Ricerca Traslazionale
Recruiting
Last update posted :
04/11/2019
Initiation :
09/21/2018
Primary completion :
09/01/2020
Completion :
09/01/2020
MET
|
MET amplification • MET exon 14 mutation • MET mutation
|
Cabometyx (cabozantinib tablet)
Phase 1
Mirati Therapeutics Inc.
Completed
Last update posted :
02/12/2019
Initiation :
06/01/2008
Primary completion :
09/01/2018
Completion :
01/01/2019
MET • AXL
|
MET amplification • MET mutation • AXL expression • MET expression
|
glesatinib (MGCD265)
Phase 2
David M. Jackman, MD
Completed
Last update posted :
02/23/2018
Initiation :
02/01/2010
Primary completion :
05/01/2015
Completion :
01/01/2017
EGFR • KRAS • MET
|
KRAS mutation • EGFR mutation • EGFR T790M • MET amplification • EGFR exon 20 insertion • MET mutation
|
erlotinib
Phase 1
AbbVie (prior sponsor, Abbott)
Completed
Last update posted :
11/21/2017
Initiation :
10/06/2011
Primary completion :
04/27/2017
Completion :
04/27/2017
MET
|
MET amplification
|
Erbitux (cetuximab) • erlotinib • 5-fluorouracil • docetaxel • irinotecan • leucovorin calcium • telisotuzumab (h224G11)
Phase 2
University Health Network, Toronto
Not yet recruiting
Last update posted :
11/21/2017
Initiation :
04/01/2013
Primary completion :
04/01/2015
Completion :
09/01/2015
MET
|
MET amplification
|
Cabometyx (cabozantinib tablet)
Phase 2
Fondazione Ricerca Traslazionale
Recruiting
Last update posted :
10/25/2017
Initiation :
12/01/2014
Primary completion :
06/01/2018
Completion :
12/01/2018
MET • ROS1
|
MET amplification • MET exon 14 mutation • ROS1 positive • MET mutation • MET amplification + MET Exon 14 mutation
|
Xalkori (crizotinib)
Phase 2
Eastern Cooperative Oncology Group
Withdrawn
Last update posted :
10/19/2017
Initiation :
03/06/2015
Primary completion :
03/06/2018
Completion :
03/06/2020
HER-2 • MET
|
HER-2 negative • MET amplification • MET expression • MET-H
|
5-fluorouracil • oxaliplatin • leucovorin calcium • AMG 337
Phase N/A
Duke University
Completed
Last update posted :
08/01/2017
Initiation :
03/01/2014
Primary completion :
05/19/2016
Completion :
07/19/2016
MET
|
MET amplification
Phase 1
Jiangsu Simcere Pharmaceutical Co., Ltd.
Recruiting
Last update posted :
01/23/2017
Initiation :
10/01/2015
Primary completion :
10/01/2017
Completion :
02/01/2018
MET
|
MET amplification
|
metatinib tromethamine (BMS-794833)
Phase 2
Chinese PLA General Hospital
Recruiting
Last update posted :
11/02/2016
Initiation :
07/01/2016
Primary completion :
10/01/2017
Completion :
07/01/2018
EGFR • ALK • MET • ROS1
|
MET amplification • ALK positive • ROS1 positive • ALK translocation • EGFR wild-type
|
Avastin (bevacizumab) • Xalkori (crizotinib)
Phase 1
Sanofi
Completed
Last update posted :
04/13/2016
Initiation :
07/01/2011
Primary completion :
04/01/2016
Completion :
04/01/2016
MET
|
MET amplification • MET positive • MET expression • MET-H
|
SAR 125844
Phase 1
M.D. Anderson Cancer Center
Completed
Last update posted :
04/13/2016
Initiation :
10/01/2011
Primary completion :
03/01/2015
Completion :
03/01/2015
EGFR • HER-2 • ALK • MET • EML4
|
EGFR mutation • HER-2 amplification • MET amplification • MET mutation • ALK translocation
|
Herceptin (trastuzumab) • lapatinib • Votrient (pazopanib)
Phase 2
Sanofi
Completed
Last update posted :
03/23/2016
Initiation :
11/01/2015
Primary completion :
01/01/2016
Completion :
01/01/2016
MET
|
MET amplification
|
SAR 125844
Phase 1
Sanofi
Completed
Last update posted :
02/17/2016
Initiation :
09/01/2012
Primary completion :
01/01/2016
Completion :
01/01/2016
MET
|
MET amplification
|
SAR 125844
Phase 1
Pfizer
Completed
Last update posted :
10/28/2015
Initiation :
08/01/2010
Primary completion :
02/01/2014
Completion :
02/01/2014
EGFR • HER-2 • KRAS • ALK • PIK3CA • MET • ROS1
|
KRAS mutation • EGFR mutation • HER-2 amplification • PIK3CA mutation • MET amplification • EGFR amplification • ALK rearrangement • ALK amplification • EGFR mutation + PIK3CA mutation • ALK rearrangement + PIK3CA mutation
|
Xalkori (crizotinib) • Vizimpro (dacomitinib)
Phase 1
Amgen
Completed
Last update posted :
12/16/2014
Initiation :
12/01/2008
Primary completion :
02/01/2013
Completion :
12/01/2014
MET
|
MET amplification • MET mutation • MET expression
|
AMG 208